Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIERRE-PK: Pharmacokinetic Profile of Nusinersen Administered Via the ThecaFlex DRx System
NCT06555419Phase 1Recruiting
- Sponsor
- Biogen
- Start
- Jan 2025
- Primary completion
- Sep 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 7
01
Overview
Phase 1, open-label trial of nusinersen in spinal muscular atrophy (SMA) (2 arms), sponsored by Biogen. Primary endpoints: Maximum Observed Concentration and Area Under the Plasma Concentration-Time Curve From Zero Time to 24 Hours. Started Jan 2025; status: recruiting.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT06555419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555419.